



Program Pack


Cystic Fibrosis (mRNA-3692/VX-522)

First inhaled pulmonary mRNA therapeutic program now in clinic for Cystic Fibrosis (CF)

First collaboration between Moderna and Vertex to address Cystic Fibrosis

**~5,000
patients**


have a mutation
that does not
make CFTR protein



mRNA-3692 / VX-522 is in a Phase 1/2 SAD/MAD study in people with CF who have a mutation that does not make the CFTR protein.

Vertex shared they have implemented a temporary pause to the multiple ascending dose (MAD) portion of the Phase 1/2 study in order to assess a tolerability issue

Science Day 2022 Summary



We have developed a **new LNP** formulation that enables efficient delivery of mRNA to and protein expression in the **pulmonary epithelium** upon **aerosol delivery**

Our ability to do so was enabled by building in-house systems and assays for high throughput testing of **rational LNP design** strategies

Our optimized inhalation LNP demonstrates high levels of protein expression localized to the airway epithelium and is **well-tolerated** in rats and NHPs

This new LNP is **well-suited for development**, with proven scale-up, stability and ability to deliver by aerosol

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: Moderna's collaboration with Vertex to address cystic fibrosis; the potential of Moderna's inhalation LNP; clinical development activities; and expected timing for sharing data. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include those described in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date referenced on the first page.